GlassScriptPhysician profile
Gina E Butler
NPI 1619966066
$2,717.24
in general payments reported to CMS, 2019-2025
26 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $1,276 · 2023: $564 · 2024: $194 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $375.15 | 2021-2022 | |
| Vifor Pharma, INC. | $303.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $293.74 | 2021-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $173.88 | 2021-2022 | |
| Nxstage Medical, INC. | $165.92 | 2023 | Nxstage System One |
| Abbvie INC. | $159.87 | 2023-2025 | |
| Akebia Therapeutics INC | $137.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2024 | |
| Opko Pharmaceuticals, LLC | $115.34 | 2021-2022 | |
| Corcept Therapeutics | $109.65 | 2023 | Korlym |
| Calliditas Therapeutics US INC. | $101.15 | 2022-2025 | Tarpeyo |
| Neurelis, INC. | $91.35 | 2023 | Valtoco |
| Amgen INC. | $90.37 | 2021-2022 | |
| Lilly USA, LLC | $83.35 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $68.54 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.14 | 2023 | Spravato |
| Vanda Pharmaceuticals INC. | $38.55 | 2021-2025 | Fanapt |
| Mallinckrodt Hospital Products INC. | $35.10 | 2022 | |
| Revance Therapeutics, INC. | $32.96 | 2024 | Daxxify |
| Ultragenyx Pharmaceutical INC. | $32.27 | 2021 | |
| Novo Nordisk INC | $30.82 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $29.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $28.04 | 2022 | |
| Daiichi Sankyo INC. | $21.95 | 2022 | |
| Exact Sciences Corporation | $16.70 | 2023 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.